Cyclophosphamideremains the ‘gold standard’treatment for severe organ threatening systemic lupus erythematosus (SLE), especially renal and central nervous system lupus. Intravenous and oral cyclophosphamide have been compared, retrospectively, with similar two year remission rates of 73% and 90%.1 In a meta-analysis, intravenous cyclophosphamide with oral prednisone is more effective than oral prednisone alone.2 The efficacy of cyclophosphamidein lupus nephritis has been proven in multiple clinical trials, but efficacy has to be balanced with toxicity, including infection, gonadalfailure, and malignancy. Although the continued use of cyclophosphamidefor renal lupus has been challenged by a recent trial of mycophenolate mofetil, and may be challenged in the future by planned trials of biologics, it continues to be widely used. This review will touch on the traditional intravenous ‘pulse’ cyclophosphamide regimen, consider its toxicity, and contrast it with newer approaches to cyclophosphamide.
Mok CC , Ho CT , Siu YPet al.Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens . Am J Kidney Dis2001; 38: 256-264 .
2.
Bansal VK , Beto JA.Treatment of lupus nephritis: a meta-analysis of clinical trials . Am J Kidney Dis1997; 29: 193-199 .
3.
Boumpas DT , Austin III HA , Vaughn EMet al.Controlled trial of pulse methylprednisoloneversus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet1992; 340: 741-745 .
4.
Gourley MF , Austin HA, 3rd , Scott Det al.Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial . Ann Intern Med1996; 125: 549-557 .
5.
Illei GG , Austin HA , Crane Met al.Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis . Ann Intern Med2001; 135: 248-257 .
6.
Dooley MA , Hogan S , Jennette C , Falk R.Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network . Kidney Int1997; 51: 1188-1195 .
7.
Guttuso T Jr , Roscoe J , Griggs J.Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer . Lancet2003; 361: 1703-1705 .
8.
Katsifis GE , Tzioufas AG , Vlachoyiannopoulos PG , Voulgarelis M , Moutsopoulos HM , Ioannidis JP.Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus . Rheumatology (Oxford)2002; 41: 780-786 .
9.
Euler HH , Harten P , Zeuner RA , Schwab UM.Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections . J Rheumatol1997; 24: 2153-2157 .
10.
Pryor BD , Bologna SG , Kahl LE.Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus . Arthritis Rheum1996; 39: 1475-1482 .
11.
Petri M.Infection in systemic lupus erythematosus . Rheumatic Dis Clinics N Am1998; 24: 423-456 .
12.
Petri M , Allbritton J.Antibiotic allergy in SLE: a case-control study . J Rheumatol1992; 19: 265-269 .
13.
Kahl LE.Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome . J Rheumatol1994; 21: 84-86 .
14.
Boumpas DT , Austin III HA , Vaughan EM , Yarboro CH , Klippel JH , Balow JE.Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy . Ann Intern Med1993; 119: 366-369 .
15.
Mok CC , Lau CS , Wong RWS.Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy . Arthritis Rheum1998; 41: 831-837 .
16.
Wang CL , Wang F , Bosco JJ.Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus . Lupus1995; 4: 11-14 .
17.
Ioannidis JP , Katsifis GE , Tzioufas AG , Moutsopoulos HM.Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus . J Rheumatol2002; 29: 2129-2135 .
18.
Huong du L , Amoura Z , Duhaut Pet al.Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients . J Rheumatol2002; 29: 2571-2576 .
19.
McDermott EM , Powell RJ.Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide . Ann Rheum Dis1996; 55: 224-229 .
20.
Dooley MA , Patterson CC , Hogan SLet al.ACR Abstract . Arthritis Rheum2000; 42: 107-107 .
21.
McCune WJ , Somers EC , Ognenovski V , Christman G.Use of leuprolide acetate for ovarian protection during cyclophosphamide therapy of women with severe SLE: a case control study [abstract] . Arthritis Rheum2001; 44(Suppl.): S387-S387 .
22.
Masala A , Faedda R , Alagna Set al.Use of testosterone to prevent cyclophosphamide-induced azoospermia . Ann Intern Med1997; 126: 292-295 .
23.
Priftakis P , Bogdanovic G , Kokhaei P , Mellstedt H , Dalianis T.BK virus (BKV) quantification in urine samples of bone marrow transplanted patients is helpful for diagnosis of hemorrhagic cystitis, although wide individual variations exist . J Clin Virol2003; 26: 71-77 .
24.
Bedi A , Miller CB , Hanson JLet al.Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation . J Clin Oncol1995; 13: 1103-1109 .
25.
Bernatsky S , Ramsey-Goldman R , Boivin JFet al.Cancer in systemic lupus erythematosus (SLE): an international multi-centre cohort study [abstract] . Arthritis Rheum2003; 48(Suppl.): S696-S696 .
26.
Pryor B , Bologna S , Ernst C , Michalsia S , Kahl L.Risk of malignancy in cyclophosphamide-treated SLE patients [abstract] . Arthritis Rheum1993; 36(Suppl.): S91-S91 .
27.
Bateman H , Yazici Y , Leff L , Peterson M , Paget SA.Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study . Lupus2000; 9: 542-544 .
28.
Blumenfeld Z , Lorber M , Yoffe N , Scharf Y.Systemic lupus erythematosus: predisposition for uterine cervical dysplasia . Lupus1994; 3: 59-61 .
29.
Lima FR , Guerra D , Sella EMCet al.Systemic lupus erythemasotus and cervical intraepithelial neoplasia . Arthritis Rheum1998; 41(Suppl.): S66-S66 .
30.
Briggs WA , Choi MJ , Scheel PJ Jr.Successful mycophenolate mofetil treatment of glomerular disease . Am J Kidney Dis1998; 31: 213-217 .
31.
Ines LS , Petri M.Mycophenolate mofetil: an emerging therapeutic option for systemic lupus erythematosus . Acta Reumatologica Portuguesa2001; 26: 153-162 .
32.
Chan TM , Li FK , Tang CSet al.Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group . N Engl J Med2000; 343: 1156-1162 .
33.
Ginzler E , Aranow C , Buyon Jet al.A multicenter study of cymophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritisi (LN): preliminary results [abstract] . Arthritis Rheum2003; 48(Suppl.): S647-S647 .
34.
Kalunian KC , Davis JC Jr , Merrill JT , Totoritis MC , Wofsy D.Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial . Arthritis Rheum2002; 46: 3251-3258 .
35.
Boumpas DT , Furie R , Manzi Set al.A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis . Arthritis Rheum2003; 48: 719-727 .
36.
Alarcon-Segovia D , Tumlin JA , Furie RAet al.LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study . Arthritis Rheum2003; 48: 442-454 .
37.
Furie R , Stohl W , Ginzler Eet al.Safety, pharmacokinetic and pharmacodynamic results of a phase I single and double dose-escalation study of LymphoStat-B (human monoclonal antibody to BLyS) in SLE patients [abstract] . Arthritis Rheum2003; 48(Suppl.): S377-S377 .
38.
Schroeder JO , Euler HE , Loffler H.Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus . Ann Intern Med1987; 107: 344-346 .
39.
Wallace DJ , Goldfinger D , Pepkowitz SHet al.Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis . J Clin Apheresis1998; 13: 163-166 .
40.
Danieli MG , Palmieri C , Salvi A , Refe MC , Strusi AS , Danieli G.Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis . J Clin Apheresis2002; 17: 72-77 .
41.
D’Cruz D , Cuadrado MJ , Mujic Fet al.Immunosuppressive therapy in lupus nephritis . Clin Exp Rheumatol1997; 15: 275-282 .
42.
Houssiau FA , Vasconcelos C , D’Cruz Det al.Immunosuppressive therapy in lupus nephritis: the Euro-LupusNephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide . Arthritis Rheum2002; 46: 2121-2131 .
43.
Mok CC , Ho CT , Chan KW , Lau CS , Wong RW.Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine . Arthritis Rheum2002; 46: 1003-1013 .
44.
Chan TM , Li FK , Wong RW , Wong KL , Chan KW , Cheng IK.Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone . Nephron1995; 71: 321-327 .
45.
Mosca M , Neri R , Giannessi Set al.Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis . Lupus2001; 10: 253-257 .
46.
Brodsky RA , Sensenbrenner LL , Jones RJ.Complete remission in severe aplastic anemia after high-dose cyclophosphamidewithout bone marrow transplantation . Blood1996; 87: 491-494 .
47.
Brodsky RA , Petri M , Smith BDet al.Immunoblative high-dose cyclophosphamide without stem cell rescue for refractory, severe autoimmune disease . Ann Int Med1998; 129: 1031-1035 .
48.
Jones RJ , Collector MI , Barber JPet al.Characterization of mouse lymphohematopoietic stem cells lacking colony-forming activity . Blood1996; 88: 487-487 .
49.
Gordon MY , Goldman JM , Gordon-Smith EC.4-hydroperoxycyclopho-sphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells . Leuk Res1985; 9: 1017-1021 .
50.
Santos GW , Owens AH Jr.A comparison of the effects of selected cytotoxic agents on allogeneic skin graft survival in rats . Bull Hopkins Hosp1965; 116: 327-340 .
51.
Zhang Q , Mayumi H , Umesue M , Tomita Y , Nomoto K , Yasu H.Fractionated dosing of cyclophosphamide for establishing long-lasting skin allograft survival, stable mixed chimerism, and intrathymic clonal deletion in mice primed with allogeneic spleen cells . Transplantation1997; 63: 1667-1673 .
52.
Petri M , Jones RJ , Brodsky RA.High dose immunoblative cyclophosphamide without stem cell transplantation in systemic lupus erythematosus . Arthritis Rheum2003; 48: 166-173 .
53.
Gladstone DE , Prestrud AA , Pradhan Aet al.High-dose cyclophosphamide for severe systemic lupus erythematosus . Lupus2002; 11: 405-410 .
54.
Tyndall A , Fassas A , Passweg Jet al.Autologous haematopoietic stem cell transplants for autoimmune disease -feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease . Bone Marrow Transplant1999; 24: 729-734 .
55.
Traynor AE , Schroeder J , Rosa RMet al.Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study . Lancet2000356: 701-707 .
56.
Traynor AE , Barr WG , Rosa RMet al.Hematopoietic stem cell transplantation for severe and refractory lupus . Arthritis Rheum2002; 46: 2917-2923 .
